search
Back to results

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients

Primary Purpose

Spinal Muscular Atrophy

Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
GC101
Sponsored by
GeneCradle Inc
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Spinal Muscular Atrophy focused on measuring Type 1

Eligibility Criteria

0 Months - 6 Months (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Six months of age and younger on day of vector infusion with Type 1 SAM as defined by the following features: Diagnosis of SMA based on gene mutation analysis with bi-allelic SMN1 mutations (deletion or point mutations) and 2 copies of SMN2; Onset of disease before 6 months of age The patient's legal guardian(s) must be able to understand the purpose and risks of the study and voluntarily provide signed and dated informed consent prior to any study-related procedures being performed. Exclusion Criteria: Patient who has participated in a previous gene therapy research trials; Patient who has received Nusinersen and Risdiplam treatment; Patient who has AAV9 neutralizing antibody titer ≥1:200; Patient who requires non-invasive ventilatory support averaging≥16 hours/day; Patient with a point mutation in SMN2 (c.859G>C); Patient who requires non-invasive ventilatory support averaging≥16 hours/day at screening; Patient who use invasive ventilatory support or pulse oximetry < 95% saturation while awake and calm at screening; Patient who is positive for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen, hepatitis C antibody, or treponema pallidum antibody; Abnormal laboratory values considered clinically significant, including gamma-glutamyl transferase(GGT), Aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin > 3x upper limit of normal (ULN), Hemoglobin (Hgb)< 110 or >150 g/L, platelet <183x10^9/L or 614x10^9/L; Class IV patient based on Modified Ross Heart Failure Classification for Children; Patient with a history of glucocorticoid allergy; Contraindication that would interfere with the lumbar puncture procedures; Presence of an untreated active infection requiring systemic antiviral therapy at any time during the screening period; Vaccination less than 2 weeks before infusion of vector; Patient who has any concurrent clinically significant major disease or any other condition that, in the opinion of the Investigator, makes the subject unsuitable for participation in the study. Note: Other protocol defined inclusion/exclusion criteria may apply.

Sites / Locations

  • Peking University, First Hospital, Department of PediatricsRecruiting
  • Bayi Children's Hospital, Seventh Medical Center, PLA general hospitalRecruiting
  • Shengjing Hospital of China Medical UniversityRecruiting
  • Children's Hospital of Soochow UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Low dosage group

High dosage group

Arm Description

2.4x10^14 vg/person of GC101 delivered one-time intrathecally (n=3)

4.8x10^14 vg/person of GC101 delivered one-time intrathecally (n=3)

Outcomes

Primary Outcome Measures

Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Frequency of treatment-related adverse events (AEs), serious adverse events (SAEs), and changes from baseline in relevant clinical laboratory tests
Proportion of patients treated with GC101 who achieve motor milestone of sit unassisted for at least 10 seconds at 18 months of age

Secondary Outcome Measures

Ability to thrive
Ability to thrive is defined as the following at 18 months of age: does not receive nutrition through mechanical support or other non-oral method; maintains weight
Changes from baseline Children's hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) score
CHOP INTEND score ranges from 0 to 64 with higher scores indicating higher motor function
Proportion of event-free survival patients

Full Information

First Posted
April 10, 2023
Last Updated
April 22, 2023
Sponsor
GeneCradle Inc
search

1. Study Identification

Unique Protocol Identification Number
NCT05824169
Brief Title
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients
Official Title
A Multi-center, Open Label, Single-arm, Dose Ascending Clinical Trial for Evaluation of Safety and Efficacy of Gene Therapy Drug GC101 in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 25, 2023 (Actual)
Primary Completion Date
December 2025 (Anticipated)
Study Completion Date
December 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
GeneCradle Inc

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The study will evaluate safety and efficacy of intrathecal delivery of GC101 gene therapy drug as a treatment of spinal muscular atrophy Type 1 (SMA 1) patients.
Detailed Description
The purpose of this trial is to evaluate safety and efficacy of gene therapy drug GC101 in SMA 1 patients. Open-label, dose-escalation clinical trial of GC101 will be conducted in multiple centers in China. GC101 will be administrated intrathecally. Short-term safety will be evaluated in 52 weeks and enter long-term follow-up study of 5 years at will. Patients will be tested at baseline and followed up on various time points. The primary analysis for efficacy will be assessed when all patients reach 18 months of age on the motor milestone of sit unassisted for at least 10 seconds.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Spinal Muscular Atrophy
Keywords
Type 1

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
18 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Low dosage group
Arm Type
Experimental
Arm Description
2.4x10^14 vg/person of GC101 delivered one-time intrathecally (n=3)
Arm Title
High dosage group
Arm Type
Experimental
Arm Description
4.8x10^14 vg/person of GC101 delivered one-time intrathecally (n=3)
Intervention Type
Genetic
Intervention Name(s)
GC101
Intervention Description
Self-complementary AAV9 carrying a codon-optimized SMN coding sequence(coSMN1) driven by CMV enhancer and chicken β-actin promoter
Primary Outcome Measure Information:
Title
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Description
Frequency of treatment-related adverse events (AEs), serious adverse events (SAEs), and changes from baseline in relevant clinical laboratory tests
Time Frame
when patient reaches 18 months of age
Title
Proportion of patients treated with GC101 who achieve motor milestone of sit unassisted for at least 10 seconds at 18 months of age
Time Frame
when patient reaches 18 months of age
Secondary Outcome Measure Information:
Title
Ability to thrive
Description
Ability to thrive is defined as the following at 18 months of age: does not receive nutrition through mechanical support or other non-oral method; maintains weight
Time Frame
when patient reaches 18 months of age
Title
Changes from baseline Children's hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) score
Description
CHOP INTEND score ranges from 0 to 64 with higher scores indicating higher motor function
Time Frame
when patient reaches 18 months of age
Title
Proportion of event-free survival patients
Time Frame
when patient reaches 14 months of age
Other Pre-specified Outcome Measures:
Title
Proportion of patients who achieve the World Health Organization (WHO) Multicenter Growth Reference Study (MGRS) motor milestones
Description
WHO MGRS gross motor milestones and performance criteria included sitting without support for at least 10 seconds, Hands-and-knees crawling at least three in a row, standing with assistance for at least 10 seconds, walking with assistance at least five steps, standing alone for at least 10 seconds, and walking alone.
Time Frame
when patient reaches 18 months of age

10. Eligibility

Sex
All
Minimum Age & Unit of Time
0 Months
Maximum Age & Unit of Time
6 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Six months of age and younger on day of vector infusion with Type 1 SAM as defined by the following features: Diagnosis of SMA based on gene mutation analysis with bi-allelic SMN1 mutations (deletion or point mutations) and 2 copies of SMN2; Onset of disease before 6 months of age The patient's legal guardian(s) must be able to understand the purpose and risks of the study and voluntarily provide signed and dated informed consent prior to any study-related procedures being performed. Exclusion Criteria: Patient who has participated in a previous gene therapy research trials; Patient who has received Nusinersen and Risdiplam treatment; Patient who has AAV9 neutralizing antibody titer ≥1:200; Patient who requires non-invasive ventilatory support averaging≥16 hours/day; Patient with a point mutation in SMN2 (c.859G>C); Patient who requires non-invasive ventilatory support averaging≥16 hours/day at screening; Patient who use invasive ventilatory support or pulse oximetry < 95% saturation while awake and calm at screening; Patient who is positive for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen, hepatitis C antibody, or treponema pallidum antibody; Abnormal laboratory values considered clinically significant, including gamma-glutamyl transferase(GGT), Aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin > 3x upper limit of normal (ULN), Hemoglobin (Hgb)< 110 or >150 g/L, platelet <183x10^9/L or 614x10^9/L; Class IV patient based on Modified Ross Heart Failure Classification for Children; Patient with a history of glucocorticoid allergy; Contraindication that would interfere with the lumbar puncture procedures; Presence of an untreated active infection requiring systemic antiviral therapy at any time during the screening period; Vaccination less than 2 weeks before infusion of vector; Patient who has any concurrent clinically significant major disease or any other condition that, in the opinion of the Investigator, makes the subject unsuitable for participation in the study. Note: Other protocol defined inclusion/exclusion criteria may apply.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
GeneCradle, Inc. China
Phone
86-13501380583
Email
ind@bj-genecradle.com
Facility Information:
Facility Name
Peking University, First Hospital, Department of Pediatrics
City
Beijing
ZIP/Postal Code
100034
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yanbin Fan
Phone
86-13126582705
Email
fanyanbin0323@163.com
First Name & Middle Initial & Last Name & Degree
Hui Xiong
Facility Name
Bayi Children's Hospital, Seventh Medical Center, PLA general hospital
City
Beijing
ZIP/Postal Code
100700
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xiuwei Ma
Phone
86-1361111080
Email
pony007@vip.sina.com
First Name & Middle Initial & Last Name & Degree
Zhicun Feng
Facility Name
Shengjing Hospital of China Medical University
City
Shenyang
ZIP/Postal Code
110004
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ping Ma
Phone
86-15501095755
Email
maping@joinn-lab.com
First Name & Middle Initial & Last Name & Degree
Hua Wang
Facility Name
Children's Hospital of Soochow University
City
Suzhou
ZIP/Postal Code
215025
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xiaoyan Shi
Phone
86-13913532943
Email
314054161@qq.com
First Name & Middle Initial & Last Name & Degree
Jihong Tang

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients

We'll reach out to this number within 24 hrs